Quest Diagnostics (DGX) PT Lowered to $100 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Quest Diagnostics (DGX) Reports Election of Denise Morrison to Board
February 19, 2019 5:06 PM ESTQuest Diagnostics (NYSE: DGX) today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company's Board has 11 members.
Ms. Morrison served as President and Chief Executive Officer of Campbell... More
Quest Diagnostics (DGX) PT Lowered to $98 at Morgan Stanley
February 15, 2019 8:06 AM ESTMorgan Stanley analyst Ricky Goldwasser lowered the price target on Quest Diagnostics (NYSE: DGX) to $98.00 (from $101.00) while maintaining a Overweight rating.
... MoreQuest Diagnostics (DGX) PT Raised to $91 at UBS
February 15, 2019 7:43 AM ESTUBS raised its price target on Quest Diagnostics (NYSE: DGX) to $91.00 (from $90.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) PT Lowered to $93 at Citi
February 15, 2019 7:08 AM ESTCiti analyst Ralph Giacobbe lowered the price target on Quest Diagnostics (NYSE: DGX) to $93.00 (from $95.00) while maintaining a Neutral rating.
... MoreQuest Diagnostics (DGX) Misses Q4 EPS by 3c, Revenues; Offers FY19 EPS/Revenue Guidance Below Consensus
February 14, 2019 6:50 AM ESTQuest Diagnostics (NYSE: DGX) reported Q4 EPS of $1.36, $0.03 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.88 billion.
"In 2018 we grew revenues, adjusted earnings and cash from operations despite some challenges in the... More
